SCHEMBL5451401

SCHEMBL5451401

CCOc1ccc(C)cc1NC(=O)Nc1ccc(N2CCNCC2)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.51
MAPT P10636 7/20 0.51
MEN1 O00255 7/20 0.51
RAB9A P51151 5/20 0.51
TP53 P04637 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 2/20 0.51
HTT P42858 1/20 0.51
HRH3 Q9Y5N1 1/20 0.50
POLB P06746 1/20 0.47
BLM P54132 1/20 0.47
PABPC1 P11940 1/20 0.46
NPC1 O15118 3/20 0.44
PKM P14618 1/20 0.44
CLK2 P49760 2/20 0.44
DYRK1A Q13627 2/20 0.44
CLK3 P49761 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5466909 0.90 CLK2 (0.46) KMT2AMAPTMEN1RAB9ATP53
SCHEMBL5452137 0.90 MEN1 (0.55) KMT2AMAPTMEN1RAB9ATP53
SCHEMBL5465368 0.90 KMT2A (0.51) KMT2AMAPTMEN1RAB9ATP53
SCHEMBL5466937 0.88 KMT2A (0.60) KMT2AMAPTMEN1RAB9ATP53
SCHEMBL5456953 0.88 MAPT (0.51) KMT2AMAPTMEN1RAB9ATP53
SCHEMBL5458428 0.86 MAPT (0.57) KMT2AMAPTMEN1RAB9ATP53
SCHEMBL5457902 0.84 WNT3A (0.53) KMT2AMAPTMEN1RAB9ATP53
SCHEMBL5467414 0.80 CLK2 (0.51) KMT2AMAPTMEN1HTTCLK2
SCHEMBL5466996 0.80 DGAT1 (0.55) KMT2AMAPTMEN1RAB9ASMN1; SMN2
SCHEMBL5465645 0.80 CNR1 (0.52) KMT2AMAPTMEN1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 KMT2A 1350/4885MAPT 758/4885MEN1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.